260 related articles for article (PubMed ID: 34539621)
21. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
22. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
23. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.
Budde K; Sommerer C; Rath T; Reinke P; Haller H; Witzke O; Suwelack B; Baeumer D; Sieder C; Porstner M; Arns W
J Nephrol; 2015 Feb; 28(1):115-23. PubMed ID: 25192833
[TBL] [Abstract][Full Text] [Related]
24. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carroll RP; Hester J; Wood KJ; Harden PN
Nephrol Dial Transplant; 2013 Feb; 28(2):462-5. PubMed ID: 23223314
[TBL] [Abstract][Full Text] [Related]
25. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
26. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.
Wolf S; Hoffmann VS; Habicht A; Kauke T; Bucher J; Schoenberg M; Werner J; Guba M; Andrassy J
PLoS One; 2018; 13(4):e0194975. PubMed ID: 29659588
[TBL] [Abstract][Full Text] [Related]
27. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
Deng J; Lu Y; He L; Ou J; Xie H
Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
[TBL] [Abstract][Full Text] [Related]
28. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
29. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
30. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
32. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
[TBL] [Abstract][Full Text] [Related]
33. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
36. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
[TBL] [Abstract][Full Text] [Related]
37. Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.
Becker LE; Weritz B; Yi X; Gross-Weissmann ML; Waldherr R; Zeier M; Sommerer C
Transpl Int; 2015 May; 28(5):553-64. PubMed ID: 25630217
[TBL] [Abstract][Full Text] [Related]
38. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Webster AC; Lee VW; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
[TBL] [Abstract][Full Text] [Related]
39. Impact of different immunosuppressive protocols on clinical outcomes in obese kidney transplant recipients: a propensity score-matched analysis.
Serna-Higuita LM; Della Penna A; Guthoff M; Heyne N; Beer-Hammer S; Nadalin S; Martus P; Königsrainer A; Quante M
Nephrol Dial Transplant; 2023 Aug; 38(9):2052-2066. PubMed ID: 36662032
[TBL] [Abstract][Full Text] [Related]
40. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
Nikoueinejad H; Soleimani A; Mirshafiey A; Amirzargar A; Sarrafnejad A; Kamkar I; Einollahi B
Exp Clin Transplant; 2013 Feb; 11(1):12-6. PubMed ID: 23387537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]